Scholarlink

<p>Non-alcoholic fatty liver disease (NAFLD) is a disease with various levels varying from fatty liver steatosis to acute steatosis which is non-alcoholic steatohepatitis (NASH), which can develop into hepatic failure, as well as in some conditions it can develop into hepatocellular carcinoma (HCC). In the NAFLD and NASH context, aberrant microRNA (miRNA) expression has a thorough contribution to the incidence and development of these liver disorders by influencing key biological actions, involving lipid metabolism, inflammation, and fibrosis. Dysregulated miRNAs can disrupt the balance between lipid accumulation and clearance, exacerbate inflammatory responses, and promote fibrogenesis, thus advancing the severeness of the disorder from simple steatosis to more complex NASH. In the current review, the latest development concerned with the activity of complex regulatory networks of miRNA in the incidence as well as the evolution of NAFLD is to be discussed, also conferring about the miRNAs’ role in the onset, pathogenesis as well as diagnosis of NAFLD and NASH discussing miRNAs’ role as diagnostic biomarkers and their therapeutic effects on NAFLD/NASH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH

  • 期刊论文

  • 发表日期：

    2025年1月31日

查看全文
  • Reda M. Mansour,
  • Sherif S. Abdel Mageed,
  • Ahmed I. Abulsoud,
  • Ghadir A Sayed,
  • Radwa H. Lutfy,
  • Farah A. Awad,
  • Mohamed M. Sadek,
  • Abanoub A. S. Shaker,
  • Osama A. Mohammed,
  • Mustafa Ahmed Abdel-Reheim,
  • Hanan Elimam,
  • Ahmed S. Doghish

摘要

Non-alcoholic fatty liver disease (NAFLD) is a disease with various levels varying from fatty liver steatosis to acute steatosis which is non-alcoholic steatohepatitis (NASH), which can develop into hepatic failure, as well as in some conditions it can develop into hepatocellular carcinoma (HCC). In the NAFLD and NASH context, aberrant microRNA (miRNA) expression has a thorough contribution to the incidence and development of these liver disorders by influencing key biological actions, involving lipid metabolism, inflammation, and fibrosis. Dysregulated miRNAs can disrupt the balance between lipid accumulation and clearance, exacerbate inflammatory responses, and promote fibrogenesis, thus advancing the severeness of the disorder from simple steatosis to more complex NASH. In the current review, the latest development concerned with the activity of complex regulatory networks of miRNA in the incidence as well as the evolution of NAFLD is to be discussed, also conferring about the miRNAs’ role in the onset, pathogenesis as well as diagnosis of NAFLD and NASH discussing miRNAs’ role as diagnostic biomarkers and their therapeutic effects on NAFLD/NASH.